论文部分内容阅读
成功的人巨细胞病毒（HCMV）疫苗接种应能诱导中和抗体（NA）和细胞毒性T淋巴细胞（CTL）应答。纯化的HCMV糖蛋白B（gB）可诱导人和实验动物产生抗HCMVNA,表达gB的异种病毒重组体可诱导小鼠产生CTL应答。为提供HCMV候选疫苗Ⅰ期临床试验的临床前资料,本文作者检测了ALVAC-HCMV-gB（ALVAC-gB）重组体在
Successful human cytomegalovirus (HCMV) vaccination should induce neutralizing antibody (NA) and cytotoxic T lymphocyte (CTL) responses. Purified HCMV glycoprotein B (gB) induces the production of anti-HCMVNA in human and experimental animals, and gB-expressing heterologous virus recombinants induce CTL responses in mice. To provide preclinical data on Phase I clinical trials of HCMV vaccine candidates, the authors examined the effect of recombinant ALVAC-HCMV-gB (ALVAC-gB)